About the study
EXHALE-3 was a Phase 3 study of dexpramipexole, an investigational once-daily oral medicine, compared with placebo over 52 weeks in people with severe eosinophilic asthma that was not well controlled on medium- or high-dose inhaled steroids. It evaluated safety, tolerability and effect on asthma.
Who took part
The study enrolled people who:
- Were 12 years of age or older
- Had severe eosinophilic asthma not controlled on medium- or high-dose inhaled steroids
Status at Veritas
This study was ended early by the sponsor and is no longer enrolling. It is listed here as part of Veritas Clinical Research's track record as a research site.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT05813288).